Composition, kit and method for detecting neuropathy

A technology for nerve damage and detection methods, which can be used in biological testing, measuring devices, material inspection products, etc., and can solve problems such as finding glaucoma

Inactive Publication Date: 2011-05-04
NAT HOSPITAL ORG +1
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there have been no reports of finding protein markers for glaucoma by proteome analysis using blood samples, and a method for diagnosing glaucoma using protein markers in the blood of glaucoma patients is unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition, kit and method for detecting neuropathy
  • Composition, kit and method for detecting neuropathy
  • Composition, kit and method for detecting neuropathy

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0072] A. Preparation of monoclonal antibodies

[0073] (1) Immunization and collection of antibody-producing cells

[0074] The immunogen obtained as described above is administered to mammals such as rats, mice (eg inbred mouse Balb / c), rabbits and the like. The dose of the immunogen once administered is appropriately determined depending on the type of animal to be immunized, the route of administration, etc., but it is about 50 to 200 μg per animal. Immunization is mainly carried out by injecting immunogens subcutaneously or intraperitoneally. In addition, the interval of immunization is not particularly limited. After the primary immunization, booster immunizations are performed 2 to 10 times, preferably 3 to 4 times, at intervals of several days to several weeks, preferably at intervals of 1 to 4 weeks. After the initial immunization, the antibody titer in the serum of immunized animals is repeatedly measured by ELISA (Enzyme-Linked Immuno Sorbent Assay) method, etc. W...

Embodiment 1

[0115] (1) Identification of plasma proteins in patients with normal tension glaucoma, cataract, and age-related macular degeneration

[0116] Heparinized plasma was obtained from 10 normal-tension glaucoma patients with an average age of 82 years, 10 cataract patients, and 10 age-related macular degeneration patients of similar age, and were measured separately. Centrifuge the plasma to remove impurities. The plasma was further diluted to 12.5 mg / mL with 25 mM ammonium bicarbonate solution (pH 8.2), and fractionated according to molecular weight using the hollow fiber filter described in Reference Example (1). Fractionated plasma samples (1.8 mL in total, containing up to 250 μg of protein) were separated into 3 fractions by reverse-phase chromatography using AKTA explorer 10s (GE Healthcare Biosciences Co., Ltd.), and each fraction was lyophilized and redissolved in 8M in urea solution. This sample was treated with DTT·iodoacetamide, diluted 10-fold, and digested at 37° C....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

Disclosed is a method for detecting a disease associated with neuropathy such as glaucoma, which comprises measuring at least one member selected from a polypeptide depicted in any one of SEQ ID NO:1 to SEQ ID NO:15 contained in a biological sample from a patient, a mutant of the polypeptide and a fragment of the polypeptide. Also disclosed is a composition or kit for diagnosing a disease associated with neuropathy such as glaucoma.

Description

technical field [0001] The present invention relates to a composition or kit useful for the diagnosis of nerve damage. [0002] The present invention also relates to a method for detecting (or judging or identifying) nerve damage using the composition or kit. Background technique [0003] Due to advances in medical technology and changes in the social environment, diseases that occur or progress with age have attracted much attention in recent years. Typical examples are lifestyle-related diseases, which are said to occur and develop as microscopic changes in the body gradually accumulate with age. Among them, diseases mainly caused by nerve damage have become serious social problems. [0004] Nerve damage is a state in which peripheral blood vessels that supply oxygen and nutrients to tissues are narrowed and blocked due to arteriosclerosis, blood flow stagnation, and nutrients cannot be supplied to peripheral tissues sufficiently, resulting in abnormal nerve function. V...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/53C07K14/47C07K16/18C12N15/02G01N33/68
CPCG01N33/6893G01N2800/16G01N2800/168G01N2800/60
Inventor 岩田岳松野圣棚桥一裕
Owner NAT HOSPITAL ORG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap